(Q34416301)

2 August 2017

1 reference

title

Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? (English)

1 reference

2 August 2017

1 reference

van Nunen AB

1

1 reference

2 August 2017

Janssen HL

2

1 reference

2 August 2017

Wolters LM

3

1 reference

2 August 2017

Niesters HG

4

1 reference

2 August 2017

de Man RA

5

1 reference

2 August 2017

Schalm SW

6

1 reference

2 August 2017

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

52

1 reference

2 August 2017

2

1 reference

2 August 2017

139-146

1 reference

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Histological improvement after anti-viral treatment for chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Hepatitis B reactivation after lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900178-4

7 January 2021

10.1016/S0166-3542(01)00178-4

Identifiers

DOI

1 reference

2 August 2017

1 reference